drugset / Trial / NCT03293277

Safety, Pharmacokinetics and Pharmacodynamics of Intranasal Dexmedetomidine in Healthy Subjects

NCT03293277

Phase 1 Unknown 48 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

The aim of this study is to investigate the safety, pharmacokinetics, pharmacodynamics of intranasal dexmedetomidine, and comparative pharmacokinetics of intranasally and intravenously administered dexmedetomidine in healthy volunteers.

Timeline

Start
2017-07-26
Primary completion
2018-07
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexmedetomidine Other / unclassified 20 ug Intranasal
Subject Dexmedetomidine Other / unclassified 40 ug Intranasal
Subject Dexmedetomidine Other / unclassified 80 ug Intranasal

Indications

No indication recorded.